Lotos pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 906,695 | 1,013,623 | 1,121,343 | 1,910,011 | 2,121,295 | 1,986,806 | 1,665,695 | 1,826,442 |
| Profit before tax | 108,661 | 111,901 | 120,181 | 504,483 | 431,271 | 281,967 | -85,888 | -217,591 |
| Net profit | 90,870 | 94,439 | 100,474 | 426,640 | 362,167 | 232,782 | -85,888 | -217,591 |
| Equity | 292,432 | 386,872 | 487,345 | 913,984 | 1,276,152 | 1,095,992 | 939,516 | 721,925 |
| Liabilities | 239,793 | 211,920 | 0 | 390,996 | 515,937 | 594,082 | 1,096,952 | 1,126,415 |
| Non-current assets | 49,836 | 58,953 | 66,771 | 46,317 | 32,491 | 18,664 | 50,816 | 35,928 |
| Current assets | 474,756 | 536,252 | 658,082 | 1,252,670 | 1,817,805 | 1,667,765 | 1,991,331 | 1,806,815 |
| Total assets | 524,592 | 595,205 | 724,853 | 1,298,987 | 1,850,296 | 1,686,429 | 2,042,147 | 1,842,743 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 566,130 | 391,917 | 373,770 |
| Social insurance contributions | - | - | - | - | - | 41,807 | 55,677 | 72,064 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -13.3% | +11.8% | +10.6% | +70.3% | +11.1% | -6.3% | -16.2% | +9.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 17.3% | 15.9% | 13.9% | 32.8% | 19.6% | 13.8% | -4.2% | -11.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 31.1% | 24.4% | 20.6% | 46.7% | 28.4% | 21.2% | -9.1% | -30.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 10.0% | 9.3% | 9.0% | 22.3% | 17.1% | 11.7% | -5.2% | -11.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 12.0% | 11.0% | 10.7% | 26.4% | 20.3% | 14.2% | -5.2% | -11.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.8 | 0.5 | - | 0.4 | 0.4 | 0.5 | 1.2 | 1.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 125,061 | 130,790 | 158,308 | 260,457 | 223,294 | 229,246 | 199,884 | 219,174 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Lotos pharma - Social security debts
The company had no debts to Sodra
Lotos pharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Lotos pharma, UAB (code 302296095) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.83M, up 9.7% year on year, but still 8.1% below the 2023 level. Profitability weakened further in 2025, with a net loss of €217.6K and a profit margin of -11.9%, after a smaller loss of €85.9K in 2024. This compares with 2023, when the company reported net profit of €232.8K and a margin of 11.7%, showing a clear shift from profit to loss over the last two years. The balance sheet in 2025 showed total assets of €1.84M, equity of €721.9K and liabilities of €1.13M. Equity represented 39.2% of assets, while debt-to-equity stood at 1.56. Asset turnover was 0.99x, indicating revenue broadly in line with the asset base. With revenue per employee of €228.3K and profit per employee of -€27.2K, operating productivity remained solid, but earnings pressure intensified in 2025.